Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

Arthritis Research and Therapy

Volumn 8, Issue 1, 2005, Pages

  Ganson, Nancy J ^a   Kelly, Susan J ^a   Scarlett, Edna ^a   Sundy, John S ^a   Hershfield, Michael S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746995205     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar1861     Document Type: Article

References (36)

1. Becker MA: Hyperuricemia and gout. In The Metabolic and Molecular Bases of Inherited Disease 8th edition. Edited by: Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill; 2001:2513-2535.
2. Wortmann RL, Kelley WN: Gout and hyperuricemia. In Kelley's Textbook of Rheumatology 6th edition. Edited by: Ruddy S, Harris ED Jr, Sledge CB. St Louis: WB Saunders; 2001:1339-1371.
3. Terkeltaub RA: Clinical practice. Gout. N Engl J Med 2003, 349:1647-1655.
4. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M: Compliance with allopurinol therapy among managed care enrollees with gout: A retrospective analysis of administrative claims. J Rheumatol 2004, 31:1575-1581.
5. London M, Hudson PM: Uricolytic activity of purified uricase in two human beings. Science 1957, 125:937-938.
6. Kissel P, Lamarche M, Royer R: Modification of uricaemia and the excretion of uric acid nitrogen by an enzyme of fungal origin. Nature 1968, 217:72-74.
7. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, Tou C, Harvey E, Morris E, Cairo MS: A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001, 97 2998-3003.
8. Coiffier B, Mounier N, Bologna S, Ferme C, Tilly H, Sonet A, Christian B, Casasnovas O, Jourdan E, Belhadj K, et al.: Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: Results of the GRAAL1 (Groupe d'Étude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003, 21:4402-4406.
9. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF: Effect of attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem1977, 252:3582-3586.
10. Veronese FM, Harris JM: Introduction and overview of peptide and protein pegylation. Adv Drug Deliv Rev 2002, 54:453-456.
11. Harris JM, Chess RB: Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2:214-221.
12. Chua CC, Greenberg ML, Viau AT, Nucci M, Brenckman WD Jr, Hershfield MS: Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Int Med 1988, 109:114-117.
13. Kelly SJ, Delnomdedieu M, Oliverio MI, Williams LD, Saifer MGP, Sherman MR, Coffman TM, Johnson GA, Hershfield MS: Diabetes insipidus in uricase-deficient mice: A model for evaluating therapy with poly(ethylene glycol)-modified uricase. J Am Soc Nephrol 2001, 12:1001-1009.
14. Ganson N, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS: Antibodies to polyethylene glycol (PEG) during phase I investigation of PEG-urate oxidase (PEG-uricase; Puricase®) for refractory gout [abstract]. Arthritis Rheum 2004, 50:s338.
15. Greenberg ML, Hershfield MS: A radiochemical-high-performance liquid chromatographic assay for urate oxidase in human plasma. Anal Biochem 1989, 176:290-293.
16. Guidance for Industry/Bioanalytic Method Validation [http://www.fda.gov/cder/guidance/index.htm]
17. Kelley WN, Rosenbloom FM, Henderson JF, Seegmiller JE: A specific enzyme defect in gout associated with overproduction of uric acid. Proc Natl Acad Sci USA 1967, 57:1735-1739.
18. Hershfield MS, Chaffee S, Koro-Johnson L, Mary A, Smith AA, Short SA: Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc Natl Acad Sci USA 1991, 88:7185-7189.
19. Shoji A, Yamanaka H, Kamatani N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004, 51 321-325.
20. Ackerman AL, Kyritsis C, Tampe R, Cresswell P: Access of soluble antigens to the endoplasmic reticulum can explain crosspresentation by dendritic cells. Nat Immunol 2005, 6:107-113.
21. Ackerman AL, Cresswell P: Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 2004, 5:678-684.
22. Shi Y, Evans JE, Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521.
23. Gu Y, Hershfield MS, Cohen A: The danger within. N Engl J Med 2004, 350:2721-2722.
24. Agar NS, Sadrzadeh SMH, Hallaway PE, Eaton JW: Erythrocyte catalase. A somatic oxidant defense? J Clin Invest 1986, 77:319-321.
25. Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, Kurtzberg J, Markert ML, Kobayashi RH, Kobayashi AL, et al.: Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 1987, 316 589-596.
26. Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A, Hershfield MS: IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest 1992, 89:1643-1651.
27. Hershfield MS: Biochemistry and immunology of poly(ethylene glycol)-modified adenosine deaminase (PEG-ADA). In Poly(ethylene glycol) Chemistry and Biological Applications Edited by: Harris JM, Zalipsky S. Washington DC: American Chemical Society; 1997:145-154.
28. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS, et al.: A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 2002, 99:1986-1994.
29. Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, Avramis VI: Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 2004, 10:5335-5341.
30. Caliceti P, Schiavon O, Veronese FM: Immunological properties of uricase conjugated to neutral soluble polymers. Bioconjug Chem 2001, 12:515-522.
31. Richter AW, Akerblom E: Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol 1983, 70 124-131.
32. Cheng TL, Wu PY, Wu MF, Chern JW, Roffler SR: Accelerated clearance of polyethylene glycol-modified proteins by antipolyethylene glycol IgM Bioconjug Chem 1999, 10:520-528.
33. Richter AW, Akerblom E: Polyethylene glycol reactive antibodies in man: Titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol 1984, 74:36-39.
34. Wilkinson I, Jackson CJ, Lang GM, Holford-Strevens V, Sehon AH: Tolerance induction in mice by conjugates of monoclonal immunoglobulins and monomethoxypolyethylene glycol. Transfer of tolerance by T cells and by T cell extracts. J Immunol 1987, 139:326-331.
35. Chen Y, Takata M, Maiti PK, Rector ES, Sehon AH: Characterization of suppressor T cell clones derived from a mouse tolerized with conjugates of ovalbumin and monomethoxypolyethylene glycol. Cell Immunol 1992, 142:16-27.
36. Lee WY, Sehon AH: Suppression of reaginic antibodies with modified allergens. I. Reduction in allergenicity of protein allergens by conjugation to polyethylene glycol. Int Arch Allergy Appl Immunol 1978, 56:159-170.